Life science products distributor Europa Biosite has acquired AMSBIO, a UK-based premium life science product and service provider.
AMSBIO has expertise in biospecimens, as well as 3D cell culture, stem cell research, glycobiology and molecular biology — significantly bolstering Europa Biosite's offering in stem cell research and regenerative medicine.
The newly acquired company is headquartered in Oxford, UK, byt has offices across the US and the Netherlands, meaning it currently serves customers across Europe and North America.
Through Europa Biosite's acquisition of AMSBIO, the company hopes to expand its presence in the US market, while also expanding its reach into key markets of high growth.
With the acquisition of AMSBIO's human and animal biospecimen biorepository in combination with Research Donors' human blood biospecimen service, Europa Biosite can offer an enhanced portfolio of biospecimens to its clients, allowing it to meet a broader range of research needs.
Founder and CEO of AMSBIO, Alex Sim, commented: “We were in dialogue with several potential buyers and selected Europa Biosite due to it being the strongest partner to continue the growth and development of AMSBIO. Europa Biosite has proven itself to be a leader within our industry, and we are eager to continue this journey together.”
Europa Biosite's CEO, Sune Schmolker, added: “I am immensely proud to lead Europa Biosite in bringing together best-in-class life science companies with our mission to raise the standard of life science distribution. We look forward to welcoming AMSBIO’s colleagues to Europa Biosite and Alex Sim to Europa Biosite’s Group Leadership Team.”
This acquisition follows Europa Biosite's recent growth, with a five-fold increase of sales during the last five years.